Kelly Huang
About Kelly Huang
Kelly Huang serves as the Chief Operating Officer at Cardea Bio Inc. and has extensive experience in the biotechnology and pharmaceutical sectors, including leadership roles at companies like Johnson & Johnson and Obalon Therapeutics.
Current Role at Cardea Bio
Kelly Huang serves as the Chief Operating Officer at Cardea Bio Inc. since 2021. In this role, she is involved in the strategic vision of democratizing access to biosignals through the BPU™ platform. Cardea Bio is recognized for pioneering the Internet of Biology, which connects live biological signals with digital information. The company is the only mass producer of biocompatible semiconductors, focusing on applications in human health, agriculture, and environmental monitoring.
Previous Experience at Johnson & Johnson
Kelly Huang held multiple positions at Johnson & Johnson from 2002 to 2009. She served as Director and Head of R&D in Paris, France, from 2002 to 2004, and later as Director of Rx and Consumer Dermatology Technology Development in Skillman, NJ, from 2004 to 2005. Huang was then promoted to Vice President of Research & Development at Neutrogena, a Johnson & Johnson Company, where she worked from 2009 to 2011. Her tenure at Johnson & Johnson spanned various roles that contributed to her expertise in the healthcare sector.
Education and Expertise
Kelly Huang holds a Bachelor of Science degree in Chemical Engineering with a Minor in Chemistry from the University of Massachusetts, Amherst. She further advanced her education by obtaining a PhD in Chemical Engineering from Stanford University. Huang has expertise in biocompatible semiconductor technology, particularly in the development and application of the BPU™ (Biosignal Processing Unit). She also holds NACD Directorship Certification and is recognized as a Board Leadership Fellow.
Board Memberships and Leadership Roles
Since 2019, Kelly Huang has been a member of the Board of Directors at Sanova Dermatology, contributing her extensive experience in the healthcare industry. She previously served on the Board of Directors for HealthTronics Information Technology Solutions LLC from 2014 to 2015. Huang has also held executive roles at various companies, including President and Chief Executive Officer at Obalon Therapeutics from 2017 to 2020, and as an Executive Committee Member at Endo Pharmaceuticals from 2011 to 2014.
Career Progression and Key Positions
Throughout her career, Kelly Huang has held significant positions across various organizations. She was the Head of Nutri-Therapeutic at L-Nutra, Inc. from 2020 to 2021 and served as Intrexon SVP and Consumer Sector Head in 2014. Additionally, she worked as VP & General Manager at Galderma from 2015 to 2017. Her diverse experience in leadership roles has equipped her with a comprehensive understanding of the biopharmaceutical and technology sectors.